Detalhe da pesquisa
1.
Effects of repeated weight cycling on non-alcoholic steatohepatitis in diet-induced obese mice.
FASEB J
; 38(7): e23579, 2024 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38568838
2.
Atorvastatin Attenuates Diet-Induced Non-Alcoholic Steatohepatitis in APOE*3-Leiden Mice by Reducing Hepatic Inflammation.
Int J Mol Sci
; 24(9)2023 Apr 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-37175538
3.
Semaglutide Has Beneficial Effects on Non-Alcoholic Steatohepatitis in Ldlr-/-.Leiden Mice.
Int J Mol Sci
; 24(10)2023 May 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37239841
4.
A Novel, Orally Bioavailable, Small-Molecule Inhibitor of PCSK9 With Significant Cholesterol-Lowering Properties In Vivo.
J Lipid Res
; 63(11): 100293, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36209894
5.
Systemic PFOS and PFOA exposure and disturbed lipid homeostasis in humans: what do we know and what not?
Crit Rev Toxicol
; 51(2): 141-164, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33853480
6.
Alirocumab, evinacumab, and atorvastatin triple therapy regresses plaque lesions and improves lesion composition in mice.
J Lipid Res
; 61(3): 365-375, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31843957
7.
Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease.
N Engl J Med
; 377(3): 211-221, 2017 07 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-28538136
8.
Inhibition of macrophage proliferation dominates plaque regression in response to cholesterol lowering.
Basic Res Cardiol
; 115(6): 78, 2020 12 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33296022
9.
Dual targeting of hepatic fibrosis and atherogenesis by icosabutate, an engineered eicosapentaenoic acid derivative.
Liver Int
; 40(11): 2860-2876, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32841505
10.
Results, meta-analysis and a first evaluation of UNOxR, the urinary nitrate-to-nitrite molar ratio, as a measure of nitrite reabsorption in experimental and clinical settings.
Amino Acids
; 50(7): 799-821, 2018 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-29728915
11.
The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice.
Eur Heart J
; 38(32): 2499-2507, 2017 Aug 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-28637178
12.
Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin.
Eur Heart J
; 36(1): 39-48, 2015 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25142968
13.
Anacetrapib reduces (V)LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9.
J Lipid Res
; 56(11): 2085-93, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26342106
14.
Effects of Inhibition or Deletion of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) on Intracerebral Hemorrhage Volumes in Mice.
Stroke
; 51(11): e297-e298, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33070710
15.
No effects of atorvastatin (10 mg/d or 80 mg/d) on nitric oxide, prostacyclin, thromboxane and oxidative stress in type 2 diabetes mellitus patients of the DALI study.
Pharmacol Res
; 94: 1-8, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25662039
16.
Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin.
J Lipid Res
; 55(10): 2103-12, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-25139399
17.
PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE.
J Lipid Res
; 55(11): 2370-9, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-25258384
18.
A systems toxicology approach for identification of disruptions in cholesterol homeostasis after aggregated exposure to mixtures of perfluorinated compounds in humans.
Toxicol Sci
; 198(2): 191-209, 2024 Mar 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-38243716
19.
The tyrosine kinase inhibitor nilotinib targets the discoidin domain receptor DDR2 in calcific aortic valve stenosis.
Br J Pharmacol
; 179(19): 4709-4721, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35751904
20.
Fenofibrate increases very low density lipoprotein triglyceride production despite reducing plasma triglyceride levels in APOE*3-Leiden.CETP mice.
J Biol Chem
; 285(33): 25168-75, 2010 Aug 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-20501652